Show simple item record

dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorPentheroudakis, Georgeen
dc.contributor.authorLetsa, I.en
dc.contributor.authorPavlidis, Nicholasen
dc.creatorBriassoulis, E. Chen
dc.creatorPentheroudakis, Georgeen
dc.creatorLetsa, I.en
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:52:42Z
dc.date.available2018-06-22T09:52:42Z
dc.date.issued2002
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41466
dc.description.abstractBackground. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient database and examined its impact on prognosis and follow-up. Material and methods. Serum CA 15-3 levels were studied in 46 patients (26 male, 20 female, median age 61) with histologically confirmed renal cancer. Distribution for stage I/II/III/IV disease was 15/12/4/15, respectively. All but one patient underwent curative nephrectomy or biopsy. Metastases were diagnosed in 26 patients. Six patients developed lung metastases, 6 bony, 3 liver, 4 nodal and 9 patients had deposits in multiple organ systems. Results. Abnormal serum CA 15-3 values were detected in 23% of patients (6/26) with metastatic disease at the time of diagnosis of metastases. Median concentrations for patients with localised and metastatic disease were 17 and 26 U/ml, respectively (Student's t-test p = 0.019, upper limit of reference range 31.3). High marker levels were commoner in patients with lung metastases (4/11), with a median CA 15-3 value of 89 U/ml. In 11 patients with metastases prospectively followed-up, the correlation between a more than two-fold serum marker concentration increase with disease progression yielded sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 62.5, 100, 100 and 50%, respectively, not of statistical significance. The correlation between detection of marker increase and cancer relapse in 31 patients with resected tumours yielded sensitivity, specificity, PPV and NPV of 40, 95, 80 and 77%, respectively, reaching marginal statistical significance (p = 0.05). At a median follow-up of 28 months, there was a trend for better 2-year overall survival in patients with normal versus high baseline marker concentrations (89 versus 53%, Logrank p = 0.05). Among metastatic disease patients, the 2-year overall survival difference (79 versus 60%) reached statistical significance (Logrank p = 0.035). Conclusion. Despite the lack of sensitivity and a poor correlation with tumour burden, monitoring of serum CA 15-3 levels may contribute towards a more effective follow-up and treatment of patients with renal cancer, especially in the subgroup of patients with pulmonary metastases. The indications for prognostic significance of baseline marker levels in terms of overall survival may be interpreted on the basis of aggressive phenotype or tumour-host immunological interactions.en
dc.language.isoengen
dc.sourceUroOncologyen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectCancer survivalen
dc.subjectFollow upen
dc.subjectPriority journalen
dc.subjectPrognosisen
dc.subjectCancer recurrenceen
dc.subjectClinical articleen
dc.subjectMetastasisen
dc.subjectMaleen
dc.subjectCorrelation analysisen
dc.subjectLymph node metastasisen
dc.subjectDisease severityen
dc.subjectLiver metastasisen
dc.subjectLung metastasisen
dc.subjectRenal canceren
dc.subjectPatient monitoringen
dc.subjectKidney canceren
dc.subjectBiopsyen
dc.subjectAntigen detectionen
dc.subjectCa 125 antigenen
dc.subjectCa 15-3en
dc.subjectDisease markeren
dc.subjectNephrectomyen
dc.subjectPhenotypeen
dc.subjectPulmonary metastasesen
dc.subjectTumor markersen
dc.subjectValidation processen
dc.titleA retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experienceen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/1561095021000064299
dc.description.volume2
dc.description.issue4
dc.description.startingpage179
dc.description.endingpage184
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidPentheroudakis, George [0000-0002-6632-2462]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-6632-2462


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record